About us


Morley Research Consortium has been committed to high performance standards for the past sixteen years. Coming from all areas of the biotech and medical device industry, MRC professionals are passionate about their work and have years of experience successfully developing regulatory strategies and submissions as well as managing all phases (I –IV post-market) of clinical trials in a wide variety of therapeutic areas. MRC’s difference is in our people, knowledge, and results.

We have the experience not only to help develop, and execute clinical trials, but understand the need for these trials to be budget conscientious and efficient. MRC’s clients enjoy the flexibility in providing tailored solutions that meet their needs, and understanding that “a one size fits all” approach doesn’t work.

Having a solid clinical pathway and partner to bring your product to market is vital to your organization’s success. Our goal is to provide the highest level of regulatory and trial management services with expertise and quality upon which our clients can depend.

Another feature that makes MRC different from other CROs is that we assist select start-up and early stage life science companies to help raise the funds necessary in order to proceed with the process of obtaining product approval status from the U. S. Food and Drug Administration (FDA).

MRC recognizes that many of its potential clients either lack sufficient funding or have unrealistic expectations of the likely cost to achieve a successful exit strategy for their clinical trials. This is why MRC provides free clinical evaluations to satisfy regulatory and clinical trial pathways for early to mid-stage medical device, pharmaceutical, and biotech companies who are currently seeking investment opportunities from funding sources. The evaluations engage top experts from MRC for clinical budgets and timelines needed for commercialization.

MRC has partnered and currently screens for investment sources ranging from venture capital, private equity, angel organizations, and family foundations both domestically and internationally focused on life science companies. These relationships along with expert analysis for regulatory and clinical trial implementation allow early to mid-stage companies the chance to reach proper investment channels with the information needed for both clinical and funding success.